Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...

PCV13 [pneumococcal 13-valent conjugate vaccine], or cohort 3: PPSV23 followed by or preceded by PCV13, PPSV23 preceded by PCV15 [pneumococcal 15-valent conjugate vaccine], or PCV15 alone).

Advisory Committee on Immunization Practices voted overwhelmingly in support of expanding usage recommendations for pneumococcal conjugate vaccines (PCVs). Now, the shots are recommended for all ...

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 – has started pivotal trials in the prevention of both paediatric Streptococcus pneumoniae, which remains a major public health ...

Three years after the start of the COVID-19 pandemic, coverage for selected routine childhood vaccines remained below prepandemic levels.

Healthcare providers, public health officials and policymakers need to develop a greater understanding of the serious health impact of pneumococcal disease in elderly adults. In addition to ...

To protect your child, their doctor will give them the pneumococcal conjugate vaccine (PCV ... was approved in 2000, and ...

Expanded recommendations from the Advisory Committee on Immunization Practices on the use of pneumococcal conjugate vaccines may improve disease ... older who have started their vaccine series with ...

The fourth dose of 7-valent pneumococcal conjugate vaccine is recommended to be given at 12-15 months but in Canada it better fits the national schedule at 18 months, prompting this comparison.